Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.
about
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsTargeting FcRn for the modulation of antibody dynamicsFcRn overexpression in transgenic mice results in augmented APC activity and robust immune response with increased diversity of induced antibodiesCharacterization of the rabbit neonatal Fc receptor (FcRn) and analyzing the immunophenotype of the transgenic rabbits that overexpresses FcRnUsing multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway.The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics.Use of Fc-Engineered Antibodies as Clearing Agents to Increase Contrast During PET.Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice.Engineered clearing agents for the selective depletion of antigen-specific antibodiesStructure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.Electron tomography of late stages of FcRn-mediated antibody transcytosis in neonatal rat small intestineSelection of nanobodies that target human neonatal Fc receptor.Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.Clinical ramifications of the MHC family Fc receptor FcRn.FcRn overexpression in mice results in potent humoral response against weakly immunogenic antigen.Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model.A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection.Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport.Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.Overexpression of Bovine FcRn in Mice Enhances T-Dependent Immune Responses by Amplifying T Helper Cell Frequency and Germinal Center Enlargement in the Spleen.Monoclonal antibodies directed against human FcRn and their applications.Particle shape enhances specificity of antibody-displaying nanoparticles.TGEV infection up-regulates FcRn expression via activation of NF-κB signaling.NFκB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn.Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis.Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumptionMonoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond.HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn.Progress on research of chicken IgY antibody-FcRY receptor combination and transfer.Nebulization as a delivery method for mAbs in respiratory diseases.Accelerating antibody discovery using transgenic animals overexpressing the neonatal Fc receptor as a result of augmented humoral immunity.Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity.Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.Human Immunoglobulin Heavy Gamma Chain Polymorphisms: Molecular Confirmation Of Proteomic Assessment.An antidote approach to reduce risk and broaden utility of antibody-based therapeutics.
P2860
Q26798402-E6861E4A-0030-4E3C-8D8B-2CFFC3C1A056Q26822421-7A841AFB-71A4-4CB6-B91A-7B42144F564CQ28080589-306548F6-A31E-46C6-8FAD-99FFD0DC15F2Q28730212-43296AA3-C5D4-44E4-B9E4-FF27ECD649CCQ28732874-35365AA1-3603-440D-A909-551D4880F003Q30539163-D92BF180-0964-49FA-877B-C8A777FF7C99Q30566003-AFE42F96-DF0F-437B-B55E-BF667F59D1ABQ30659434-2EB33395-EE2F-41A8-B5D3-858CC579E6D7Q33758483-F2CBF164-9C85-4F09-8624-EA097CAF909AQ33766669-15E4773E-CA3D-4393-BF58-D388FB919C2FQ34244234-0C823D39-78E7-43A2-AACA-96E916A64C65Q34264316-2D56B3B6-046E-4D28-A31B-8DEB0D2CC7C4Q34560808-4DCE990C-7D1D-4A6A-A4A8-8F49B9633899Q34693822-137BFD6D-5BC9-4392-ADE2-A748B50B1E26Q34754673-8FF0FBD8-D6E0-4E2F-B374-0CDE57B71C7AQ34974778-94A0181E-2531-4236-ABB4-FBB045F28D6DQ35170050-CC8DA3AF-E414-4E37-81AA-B7D20E30FB1DQ35274924-195ADCC4-2143-4009-B6BC-87F0E4F47E4DQ35546930-8A5BD246-3CE3-4FC0-AC81-65BE40C59197Q35578023-ACF625F2-73C9-4354-A4BF-52875975CCC9Q35612850-1E4297CD-CE5F-47F5-B2D3-FDBACA97C32CQ35670904-46BA26EB-5BF7-421D-92B1-18B5F99636B8Q35866344-7D306799-5072-4626-B909-18581F866468Q35992498-686CEB15-8C23-466C-A7DC-6781598B8058Q36653978-E81CE10F-3CC4-46E4-A029-CF5F3BB2203BQ37198590-D8CF8F4F-9844-4C75-8572-E512C5B22896Q37496557-5B3C3BD2-2228-4E90-9C57-FE235892C93FQ37688076-668D7BBD-FAE2-48CF-82D5-202917E62333Q37709509-84A66865-9B4E-4F2A-AB49-B9CCBB0032FEQ37819809-A222B202-7830-4A1D-BE66-7D6B3B1303AAQ37998314-AD631A7D-FB94-41AE-AE51-85F76DA393A0Q38020355-439678BA-3F76-4AB3-9496-32082B300234Q38024147-5C4416F3-93E7-4977-A24D-8F3176FA2244Q38306677-45A7C9DF-5D83-495D-8C5C-DDF9AB74947AQ38615389-E10FBCA7-D4DE-4F01-A6CA-7A9AF06A2B39Q38615394-5B10E037-1B82-4EFC-BD87-86B956E20804Q38718049-14FC4448-38A8-49DE-9053-7A88257FE5B3Q38883267-F9CC906A-3336-41BE-A35D-A6D0FCE3BC96Q40306045-54EFBCDE-467D-4369-926A-0286DDB2ED65Q40309222-3E987AAF-2892-4468-A1CF-4D9CF5AE6578
P2860
Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chapter 4: Multitasking by exp ...... ctions the many faces of FcRn.
@en
Chapter 4: Multitasking by exp ...... ctions the many faces of FcRn.
@nl
type
label
Chapter 4: Multitasking by exp ...... ctions the many faces of FcRn.
@en
Chapter 4: Multitasking by exp ...... ctions the many faces of FcRn.
@nl
prefLabel
Chapter 4: Multitasking by exp ...... ctions the many faces of FcRn.
@en
Chapter 4: Multitasking by exp ...... ctions the many faces of FcRn.
@nl
P2860
P1476
Chapter 4: Multitasking by exp ...... nctions the many faces of FcRn
@en
P2093
E Sally Ward
Raimund J Ober
P2860
P304
P356
10.1016/S0065-2776(09)03004-1
P577
2009-01-01T00:00:00Z